Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Short-term Investments (2022 - 2024)

Atara Biotherapeutics (ATRA) has disclosed Short-term Investments for 4 consecutive years, with $5.4 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Short-term Investments rose 36.25% year-over-year to $5.4 million, compared with a TTM value of $5.4 million through Jun 2025, up 36.25%, and an annual FY2024 reading of $17.5 million, down 32.52% over the prior year.
  • Short-term Investments was $5.4 million for Q2 2025 at Atara Biotherapeutics, up from $146000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $200.3 million in Q3 2022 and bottomed at $146000.0 in Q4 2022.
  • Average Short-term Investments over 4 years is $34.8 million, with a median of $4.7 million recorded in 2024.
  • Peak annual rise in Short-term Investments hit 17628.77% in 2023, while the deepest fall reached 99.93% in 2023.
  • Year by year, Short-term Investments stood at $146000.0 in 2022, then soared by 17628.77% to $25.9 million in 2023, then tumbled by 32.52% to $17.5 million in 2024, then plummeted by 68.97% to $5.4 million in 2025.
  • Business Quant data shows Short-term Investments for ATRA at $5.4 million in Q2 2025, $146000.0 in Q1 2025, and $17.5 million in Q4 2024.